Get the Stockscreener App
5.69
2.74%
-0.16
After Hours:
5.71
0.02
+0.35%
Mind Medicine Inc stock is traded at $5.69, with a volume of 645.64K.
It is down -2.74% in the last 24 hours and down -6.11% over the past month.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$5.85
Open:
$5.82
24h Volume:
645.64K
Relative Volume:
0.61
Market Cap:
$463.34M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-2.8593
EPS:
-1.99
Net Cash Flow:
$-64.37M
1W Performance:
-3.07%
1M Performance:
-6.11%
6M Performance:
-39.47%
1Y Performance:
+81.79%
1-Day Range:
$5.56
$5.94
1-Week Range:
$5.56
$6.11
52-Week Range:
$2.41
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Marshall Wace LLP Has $15.58 Million Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed executive sells over $26k in company stock By Investing.com - Investing.com South Africa
MindMed executive sells over $26k in company stock By Investing.com - Investing.com Australia
Mind Medicine's chief medical officer sells shares worth over $41,000 - Investing.com
MindMed CEO Robert Barrow sells shares worth over $118,000 - Investing.com India
Mind Medicine's chief medical officer sells shares worth over $41,000 By Investing.com - Investing.com UK
Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma - Barchart
Rhumbline Advisers Makes New $679,000 Investment in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Generalized Anxiety Disorder Global Market is Booming Across - openPR
(MNMD) Proactive Strategies - Stock Traders Daily
Mankind Pharma: Rs 10000 crore fund raise via this routeDetails - ET Now
Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18
Mankind Pharma board approves up to Rs 10,000-crore fund raise via NCDs, CPs - Moneycontrol
Mount Sinai Opens New Psychedelic Research Center in NYC - Mirage News
Psychedelic research at a crossroads - Science
Director GRYSKA DAVID W acquired 3,500 shares of Mind Medicine Inc [MNMD] - Knox Daily
Bank of New York Mellon Corp Buys 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Wall Street analysts’ outlook for Mind Medicine Inc (MNMD) - SETE News
Examining the Potential Price Growth of Mind Medicine Inc (MNMD) - Knox Daily
Long Strange Trip Continues for Psychedelics in PTSD, TRD - Managed Healthcare Executive
A closer look at Mind Medicine Inc (MNMD)’s stock price trends - US Post News
Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World
Mannkind Corp (MNKD) gets rating Resumed from Leerink Partners - Knox Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) PT Lowered to $14.00 at Canaccord Genuity Group - MarketBeat
Trend Tracker for (MNMD) - Stock Traders Daily
MindMed Issues New Employee Share Options - TipRanks
MindMed Announces New Employee Inducement Grants - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Rating of "Buy" by Analysts - MarketBeat
MindMed Showcases Innovation at Investor Events - TipRanks
MindMed to Participate in September Investor Conferences - StockTitan
MindMed to Participate in September Investor Conferences - Yahoo Finance
Mind Medicine (MindMed) Inc. Expected to Earn Q3 2024 Earnings of ($0.27) Per Share (NASDAQ:MNMD) - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target Raised to $55.00 - MarketBeat
(MNMD) Long Term Investment Analysis - Stock Traders Daily
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Canada
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Director Acquires $20,930.00 in Stock - MarketBeat
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Australia
Mind medicine director David Gryska buys $20,930 in company shares - Investing.com India
Mind medicine director David Gryska buys $20,930 in company shares - Investing.com
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com UK
Mind Medicine Inc’s $75 Million Common Shares Offering - Global Legal Chronicle
Mind Medicine: Pumping Up The Balance Sheet (Again) (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com India
Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com
Mind Medicine CEO Robert Barrow buys $6,215 in shares By Investing.com - Investing.com UK
Mind Medicine Highlights GAD’s Economic Impact - TipRanks
MindMed to Showcase at Neuro Conference - TipRanks
MindMed to Engage in Canaccord Genuity Growth Event - TipRanks
MindMed to Present at Oppenheimer Healthcare Conference - TipRanks
MindMed Unveils GAD Treatment Study at Key Conferences - TipRanks
MNMD (Mind Medicine) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):